Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model

[1]  I. Gozes.  NAP (davunetide) provides functional and structural neuroprotection. , 2011, Current pharmaceutical design.

[2]  Sarah A. Stern,et al.  Astrocyte-Neuron Lactate Transport Is Required for Long-Term Memory Formation , 2011, Cell.

[3]  Bruce H. Morimoto,et al.  A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions , 2011, Molecular and Cellular Neuroscience.

[4]  P. Gressens,et al.  Neuroprotective effects of NAP against excitotoxic brain damage in the newborn mice: implications for cerebral palsy , 2011, Neuroscience.

[5]  D. Javitt.  EFFECTS OF INTRANASAL AL-108 (DAVUNETIDE) ON NEUROCOGNITION AND FUNCTIONAL OUTCOME IN SCHIZOPHERENIA , 2010, Schizophrenia Research.

[6]  N. Calcutt,et al.  The pathological interaction between diabetes and presymptomatic Alzheimer's disease , 2009, Neurobiology of Aging.

[7]  Bruce H. Morimoto,et al.  Addressing Alzheimer's disease tangles: from NAP to AL-108. , 2009, Current Alzheimer research.

[8]  Liji Jin,et al.  Aucubin prevents loss of hippocampal neurons and regulates antioxidative activity in diabetic encephalopathy rats , 2009, Phytotherapy research : PTR.

[9]  J. Moriguti,et al.  (Pre)diabetes, brain aging, and cognition. , 2009, Biochimica et biophysica acta.

[10]  Li-ping Yang,et al.  Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy. , 2009, Investigative ophthalmology & visual science.

[11]  G. Pell,et al.  Central Nervous System Function in Youth With Type 1 Diabetes 12 Years After Disease Onset , 2009, Diabetes Care.

[12]  U. Tuor,et al.  Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. , 2008, Brain : a journal of neurology.

[13]  K. Chopra,et al.  Neuroprotective effect of N-acetylcysteine in the development of diabetic encephalopathy in streptozotocin-induced diabetes , 2008, Metabolic Brain Disease.

[14]  P. Aisen,et al.  A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease , 2008, Journal of Pharmacology and Experimental Therapeutics.

[15]  M. Mattson,et al.  Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons , 2008, Nature Neuroscience.

[16]  Jianwei Zhou,et al.  Expression changes of growth-associated protein-43 (GAP-43) and mitogen-activated protein kinase phosphatase-1 (MKP-1) and in hippocampus of streptozotocin-induced diabetic cognitive impairment rats , 2007, Experimental Neurology.

[17]  C. Guerri,et al.  The peptide NAP promotes neuronal growth and differentiation through extracellular signal‐regulated protein kinase and Akt pathways, and protects neurons co‐cultured with astrocytes damaged by ethanol , 2007, Journal of neurochemistry.

[18]  Bin Zhang,et al.  Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model , 2007, Neuron.

[19]  J. Argente,et al.  Activation of the intrinsic cell death pathway, increased apoptosis and modulation of astrocytes in the cerebellum of diabetic rats , 2006, Neurobiology of Disease.

[20]  Bruce H. Morimoto,et al.  NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). , 2006, CNS drug reviews.

[21]  Geert Jan Biessels,et al.  Cognitive Performance, Psychological Well-Being, and Brain Magnetic Resonance Imaging in Older Patients With Type 1 Diabetes , 2006, Diabetes.

[22]  Jeroen van der Grond,et al.  Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. , 2006, Diabetes.

[23]  C. Grillo,et al.  Immunocytochemical analysis of synaptic proteins provides new insights into diabetes-mediated plasticity in the rat hippocampus , 2005, Neuroscience.

[24]  G. Biessels,et al.  The impact of diabetes on cognition: What can be learned from rodent models? , 2005, Neurobiology of Aging.

[25]  Michael E. Hasselmo,et al.  A Model of Prefrontal Cortical Mechanisms for Goal-directed Behavior , 2005, Journal of Cognitive Neuroscience.

[26]  Y. Ben-Shaul,et al.  Chronic cholinergic imbalances promote brain diffusion and transport abnormalities , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  T. Gardner,et al.  Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. , 2005, Diabetes.

[28]  G J Barker,et al.  Whole-brain T2 mapping demonstrates occult abnormalities in focal epilepsy , 2005, Neurology.

[29]  L. Mittelman,et al.  A Femtomolar Acting Octapeptide Interacts with Tubulin and Protects Astrocytes against Zinc Intoxication* , 2004, Journal of Biological Chemistry.

[30]  S. Waxman,et al.  Apoptosis of vasopressinergic hypothalamic neurons in chronic diabetes mellitus , 2004, Neurobiology of Disease.

[31]  Klaas Nicolay,et al.  Magnetic Resonance Imaging in Experimental Models of Brain Disorders , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[32]  A. Goldsweig,et al.  Activity-dependent neuroprotective protein: a novel gene essential for brain formation. , 2003, Brain research. Developmental brain research.

[33]  I. Gozes,et al.  NAP, a Femtomolar-Acting Peptide, Protects the Brain Against Ischemic Injury by Reducing Apoptotic Death , 2002, Stroke.

[34]  E. Ling,et al.  Neuronal and glial response in the rat hypothalamus–neurohypophysis complex with streptozotocin-induced diabetes , 2002, Brain Research.

[35]  Willem Hendrik Gispen,et al.  Cognition and synaptic plasticity in diabetes mellitus , 2000, Trends in Neurosciences.

[36]  I. Gozes,et al.  Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. , 2000, The Journal of pharmacology and experimental therapeutics.

[37]  H. Bassan,et al.  Complete Sequence of a Novel Protein Containing a Femtomolar‐Activity‐Dependent Neuroprotective Peptide , 1999, Journal of neurochemistry.

[38]  W. Gispen,et al.  B-50, the growth associated protein-43: modulation of cell morphology and communication in the nervous system , 1997, Progress in Neurobiology.

[39]  Jesper Mogensen,et al.  Prefrontal cortical mediation of rats' place learning in a modified water maze , 1995, Brain Research Bulletin.

[40]  T. Bliss,et al.  A synaptic model of memory: long-term potentiation in the hippocampus , 1993, Nature.

[41]  Bruce H. Morimoto,et al.  Davunetide Pharmacokinetics and distribution to brain after intravenous or intranasal administration to rat , 2009 .

[42]  C. Plata-salamán,et al.  Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures , 2007, Journal of Molecular Neuroscience.

[43]  I. Gozes,et al.  Brain injury-dependent expression of activity-dependent neuroprotective protein , 2007, Journal of Molecular Neuroscience.

[44]  H. Soreq,et al.  Neuronal overexpression of ‘readthrough’ acetylcholinesterase is associated with antisense-suppressible behavioral impairments , 2002, Molecular Psychiatry.

[45]  N. van Bruggen,et al.  The application of magnetic resonance imaging to the study of experimental cerebral ischaemia. , 1994, Cerebrovascular and brain metabolism reviews.

[46]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .